Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB033 single ascending dose study in healthy adults
NL-OMON32724Phase 1Active, not recruiting
- Sponsor
- Biogen
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicinumab in multiple sclerosis (MS) and demyelinating disease (8 cohorts), sponsored by Biogen. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 2 more. Started Jan 2010; status: active, not recruiting.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)demyelinating disease
Beyond the preview
Go deeper on NL-OMON32724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32724.